TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 7.90nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 7.90nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 11nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 18nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 25nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 29nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 38nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 39nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 44nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 50nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 63nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 85nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 89nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 98nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 100nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 102nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 125nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 126nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 158nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 158nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 200nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 200nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 251nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 295nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 309nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 316nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 316nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 331nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 447nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 457nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 468nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 468nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 490nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 501nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 501nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 575nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 631nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 794nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 832nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 933nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.00E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.18E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.26E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.38E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.45E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.59E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.59E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.62E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.74E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Homo sapiens (Human))
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 2.00E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells assessed as increase in relative fluorescence unit measured for 2 mins by FLIPR based membr...More data for this Ligand-Target Pair